VO2 max is now recognised as one of the single strongest predictors of long-term cardiovascular health and all-cause mortality, yet most people have never measured it and fewer still are training to improve it. Improve how you assess, target and systematically raise your cardiorespiratory fitness for lifelong cardiovascular protection. Take away specific solutions to: Understand why VO2 max predicts cardiovascular and all-cause mortality more powerfully than almost any other measurable biomarker Evaluate the training protocols, Zone 2, high-intensity intervals and periodisation, with the strongest evidence for improving cardiorespiratory fitness across age groups Apply a structured, evidence-based fitness framework that moves VO2 max in the right direction regardless of your current starting point Achieve the cardiovascular fitness levels that longevity science identifies as genuinely protective, and measure your progress with the metric that matters most

High blood pressure remains the single largest modifiable risk factor for cardiovascular disease and stroke, yet millions of people are walking around with arterial damage accumulating silently. Advance your understanding of the mechanisms driving hypertension and arterial stiffness and what evidence-based intervention actually looks like. Source practical tips to:

• Examine the relationship between arterial stiffness, endothelial dysfunction and hypertension and why standard blood pressure measurement misses important early signals
• Evaluate the dietary, lifestyle, supplementation and clinical interventions with the strongest evidence for reducing arterial stiffness and restoring vascular health
• Build a proactive hypertension management framework that goes beyond medication to address the root drivers of vascular aging

Achieve the vascular health your cardiovascular longevity depends on, before silent damage becomes an irreversible crisis

Atrial fibrillation is the most common cardiac arrhythmia in adults over 50, and its connection to stroke, cognitive decline and cardiovascular mortality makes early detection and management one of the highest-leverage longevity interventions available. Improve how you identify risk, interpret emerging detection tools and apply evidence-based strategies to protect your cardiovascular trajectory. Take away specific solutions to:

• Decode the relationship between AF, stroke risk and cognitive decline and understand why early detection changes long-term outcomes so dramatically
• Evaluate the role of continuous cardiac monitoring, wearable ECG technology and clinical screening in identifying AF before it causes irreversible harm
• Apply a comprehensive risk reduction framework covering lifestyle, clinical intervention and monitoring that addresses AF as the serious longevity threat it represents

Achieve the cardiovascular protection that early AF detection and evidence-based management make possible, before it becomes the crisis that changes everything

Regenerative therapies are moving from experimental fringe to clinical reality, but the pace of commercial adoption is significantly outrunning the evidence, and knowing the difference matters. Advance how you evaluate the regenerative landscape with the scientific rigour it demands. Source practical tips to:

• Examine where stem cell therapy, exosomes and platelet-rich plasma sit on the evidence spectrum from robust clinical validation to promising but premature
• Distinguish the regenerative interventions approaching mainstream clinical application from those still years away from meaningful human evidence
• Build a framework for evaluating regenerative therapy claims that separates legitimate clinical progress from expensive, unregulated experimentation

Achieve a clear-eyed, evidence-based position on regenerative medicine, and know exactly what you are considering before you pursue it

Partial epigenetic reprogramming has produced extraordinary results in animal models, reversing biological age markers and restoring function in aged tissues. Improve how you understand where this technology genuinely stands and what its realistic timeline to human application looks like. Take away specific solutions to:

• Unpack the science behind Yamanaka factor reprogramming, what it has demonstrated in preclinical research and why translation to humans is far more complex
• Evaluate the companies and research programmes at the forefront of epigenetic reprogramming and assess their clinical credibility and development timelines
• Position your understanding of reprogramming science to make informed decisions as therapies move closer to human trials and eventual clinical access

Achieve a sophisticated grasp of longevity science’s most transformative frontier, grounded in what the evidence actually shows today